Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study. (31st March 2019) - Plesner, Torben; Arkenau, Hendrik‐Tobias; Gay, Francesca; Minnema, Monique C.; Boccadoro, Mario; Moreau, Philippe; Cavenagh, Jamie; Perrot, Aurore; Laubach, Jacob P.; Krejcik, Jakub; Ahmadi, Tahamtan; de Boer, Carla; et al.